Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.35 |
| ▸ | HPGD | P15428 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.34 |
| ▸ | SYK | P43405 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718764 | 0.81 | MEN1 (0.49) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL76562 | 0.78 | GAA (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL2900606 | 0.74 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL1145317 | 0.72 | TRPV4 (0.52) | KDM4ESYKHSD17B10CYP2C9 | |
| SCHEMBL19806054 | 0.72 | KDM4E (0.60) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL19805930 | 0.72 | SDHB (0.57) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL19805755 | 0.71 | MEN1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL29976028 | 0.71 | MEN1 (0.40) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL20985669 | 0.71 | KDM4E (0.61) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL28307445 | 0.70 | MEN1 (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235560-B2 | Pyrimidine derivative as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235560-B2 | Pyrimidine derivative as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| US-7235560-B2 | Pyrimidine derivative as selective COX-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2007-06-26 | — | — | US | disclosed |
| EP-1546128-B1 | PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20060040967-A1 | Pyrimidine derivative as selelctive cox-2 inhibitors | GLAXO GROUP LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1546128-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004018452-A1 | PYRIMIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS | GLAXO GROUP LIMITED (GB) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040967-A1 | Pyrimidine derivative as selelctive cox-2 inhibitors | PTGES2, PTGS2, DPYD | MEN1 4299/4885KMT2A 3236/4885ALDH1A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.